氟伏沙明
舍曲林
西酞普兰
氟西汀
帕罗西汀
惊恐障碍
依西酞普兰
抗抑郁药
医学
5-羟色胺摄取抑制剂
再摄取抑制剂
药理学
安慰剂
抗焦虑药
5-羟色胺再摄取抑制剂
5-羟色胺能
心理学
血清素
精神科
内科学
焦虑
替代医学
受体
病理
作者
Marina Dyskant Mochcovitch,Antônio Egídio Nardi
摘要
The selective serotonin-reuptake inhibitors are widely used in clinical practice in the treatment of panic disorder (PD). This article undertakes an up-to-date, systematic review of the published double-blind, placebo-controlled, randomized, short-term studies with currently available selective serotonin-reuptake inhibitors in the treatment of PD. Sertraline, paroxetine, citalopram, escitalopram, fluoxetine and fluvoxamine have all been proven to be superior to pill-placebo, although the placebo effect has been shown to be extremely important in patients with PD. The authors also explore the anxiolytic mechanism of action of this antidepressant drug class and the preclinical studies that are being developed to clarify the etiopathogenic mechanisms of PD and, more precisely, the role of the serotoninergic system in this pathogenesis. These steps are considered fundamental for the improvement of pharmacological treatment of PD.
科研通智能强力驱动
Strongly Powered by AbleSci AI